Argenx to buy peptide platform in potentially billion-dollar deal
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 9 11:27 ETSource: BioPharma Dive
From the source
Read at biopharmadive.comArgenx to buy peptide platform in potentially billion-dollar deal
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
